MSD
Hertford Road
Hoddesdon
Hertfordshire EN11 9BU
UK
Telephone [redacted]
Facsimile [redacted]

2nd April 2015

Dear Meindert,

Re. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, abatacept and tocilizumab for the treatment of rheumatoid arthritis (review of TA guidance 130, 186, 224, 234 and part review of TA guidance 225 and 247) [ID537]

MSD has reviewed the consultation documents relating to the Decision Support Unit analysis. The analysis seems to have been conducted with the intention of confirming the prior Assessment Group assumptions. We do not feel that this analysis has moved the situation forward sufficiently to warrant the second appraisal committee meeting scheduled for the 21st May.

Kind regards,

[redacted]

[redacted]